Genetic testing in liver diseases: Clinical applications Authors: Verena Keitel, Anne Mentzinger, Carola Dröge, Silvia Vilarinho Published: 2026 ABSTRACT SummaryHuman genetics has long been a cornerstone to elucidate the molecular basis of disease. Completion of the human genome sequence, together with major technological advances, has dramatically reduced sequencing costs while increasing the scale, accuracy, and interpretability of genomic data. These developments have accelerated the clinical translation of genomic testing. Although genomic medicine has been most widely adopted in paediatrics, neurology, and oncology, its application in adult hepatology is expanding rapidly. This review synthesises the growing body of evidence supporting the use of genetic testing in the diagnosis and management of adults across a broad spectrum of liver diseases, including cholestatic disorders, unexplained hepatic steatosis, cryptogenic cirrhosis, idiopathic portal hypertension, and acute liver failure. We highlight high-yield learning points and actionable clinical insights relevant to real-world practice, and we emphasise the importance of specialised centres with expertise in genomic hepatology, including multidisciplinary Hepatology Genome Rounds. Finally, we present our perspective on the current state and near-term future of a liver-centred, integrative genomic ecosystem and its anticipated impact on the training and practice of hepatology. Keypoints •Genomic analysis should be performed in the evaluation of patients with unexplained liver disease despite a comprehensive work-up.•Genetic testing enables a definitive diagnosis in at least 20-30% of adults with idiopathic cholestasis and/or cholangiopathy.•Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have monogenic diseases.•A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or portal sinusoidal vascular disease.•Rapid whole-genome sequencing is now an integral part of the evaluation of acute liver failure in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult acute liver failure of unclear aetiology remains undefined.•Like Liver Tumour Boards, Hepatology Genome Rounds represent a multidisciplinary forum that is likely to be increasingly integrated into hepatology centres with relevant expertise. Keypoints •Genomic analysis should be performed in the evaluation of patients with unexplained liver disease despite a comprehensive work-up.•Genetic testing enables a definitive diagnosis in at least 20-30% of adults with idiopathic cholestasis and/or cholangiopathy.•Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have monogenic diseases.•A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or portal sinusoidal vascular disease.•Rapid whole-genome sequencing is now an integral part of the evaluation of acute liver failure in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult acute liver failure of unclear aetiology remains undefined.•Like Liver Tumour Boards, Hepatology Genome Rounds represent a multidisciplinary forum that is likely to be increasingly integrated into hepatology centres with relevant expertise. •Genomic analysis should be performed in the evaluation of patients with unexplained liver disease despite a comprehensive work-up. Genomic analysis should be performed in the evaluation of patients with unexplained liver disease despite a comprehensive work-up. •Genetic testing enables a definitive diagnosis in at least 20-30% of adults with idiopathic cholestasis and/or cholangiopathy. Genetic testing enables a definitive diagnosis in at least 20-30% of adults with idiopathic cholestasis and/or cholangiopathy. •Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have monogenic diseases. Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have monogenic diseases. •A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or portal sinusoidal vascular disease. A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or portal sinusoidal vascular disease. •Rapid whole-genome sequencing is now an integral part of the evaluation of acute liver failure in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult acute liver failure of unclear aetiology remains undefined. Rapid whole-genome sequencing is now an integral part of the evaluation of acute liver failure in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult acute liver failure of unclear aetiology remains undefined. •Like Liver Tumour Boards, Hepatology Genome Rounds represent a multidisciplinary forum that is likely to be increasingly integrated into hepatology centres with relevant expertise. Like Liver Tumour Boards, Hepatology Genome Rounds represent a multidisciplinary forum that is likely to be increasingly integrated into hepatology centres with relevant expertise. Introduction Historically, human genetics has been a powerful means to advance our understanding of human disease. As sequencing technologies have evolved, genetic analysis has become an increasingly important component of clinical diagnosis across many fields of medicine. A central aim of genomic medicine is to identify genetic variants that contribute to disease and translate this information into improved diagnosis, risk stratification, therapeutic decision-making, and novel therapeutic approaches, which will ultimately improve patient care and quality of life. Early gene discovery efforts focused primarily on monogenic disorders.1 Beginning in the 1980s, disease-causing variants were identified through linkage analysis and positional mapping in large multiplex pedigrees. Although this approach was time-intensive and largely confined to research settings, it proved highly informative. By the year 2000, genes with disease-causing variants (pathogenic mutations) had been identified for more than 1,000 of the approximately 7,000 recognised Mendelian disorders.1 The completion of the Human Genome Project in 2003 taught us that humans harbour approximately 20,000 protein-coding genes and accelerated the study and clinical evaluation of genetic disease. Initial clinical genetic testing relied on single-gene sequencing, typically performed using low-throughput Sanger sequencing, which required a well-defined clinical phenotype to guide targeted analysis and allowed only one gene to be evaluated at a time. The advent of next-generation sequencing (NGS), also referred to as high-throughput or massively parallel sequencing, enabled simultaneous interrogation of large numbers of genes and, ultimately, the entire exome or genome. Together with the rapid expansion of population reference datasets and clinically curated variant databases, these advances have greatly expanded the diagnostic capabilities and clinical impact of genomic medicine.1,2 Among NGS-based approaches, whole-exome sequencing (WES) has emerged as a powerful diagnostic tool for patients with unexplained or atypical clinical presentations. The protein-coding exome comprises approximately 1% of the human genome yet harbours an estimated 85% of known disease-causing variants.3 By selectively sequencing these coding regions, WES enables comprehensive analysis of genes most likely to harbour pathogenic variants. The clinical potential of WES was first demonstrated in 2009 through the identification of a homozygous pathogenic variant in SLC26A3 as the cause of Bartter syndrome in a previously undiagnosed patient.4 Subsequently, over the years, multiple studies have confirmed its diagnostic utility. Recently, in a cohort of 825 patients evaluated over 6 years, WES identified a molecular diagnosis in 33.7% of cases.5 Despite these advances, the clinical application of WES has been concentrated largely in paediatrics, neurology, and oncology. In paediatric populations, WES has become a central component in the diagnostic evaluation of suspected genetic disease, as traditionally inherited causes of disease are largely thought to present early in life. Meta-analyses report molecular diagnostic yields of approximately 30–40%, and WES and whole-genome sequencing (WGS) are now widely incorporated into the clinical work-up of children with suspected Mendelian disorders.6 In contrast, genomic testing has been adopted more slowly in adult medicine, where phenotypes are often more heterogeneous and genetic aetiologies have been less readily considered in the differential diagnosis. In adult hepatology, genomic analysis has demonstrated significant potential to inform diagnosis and clinical management. It has been longstanding practice to screen for three genetic liver diseases in adults with liver function abnormalities. These include hereditary haemochromatosis, Wilson’s disease and alpha-1 antitrypsin deficiency, and represent well-established examples in which identification of pathogenic variants directly guides patient care. Molecular diagnosis of these conditions provides insight into the cellular and molecular mechanisms underlying disease pathogenesis. Subsequently, this information often informs clinical management and therapeutic decision-making, facilitates accurate prognostication, and supports family counselling.1 Beyond these well-characterised disorders, many liver phenotypes remain unexplained. Although the proportion of unexplained liver disease has declined as additional aetiologies have been recognised and more comprehensive diagnostic approaches have been adopted in clinical practice, data from the Scientific Registry of Transplant Recipients indicate that approximately 15% of adults on the liver transplant waiting list have liver disease of unknown cause.7 Recent studies suggest that genomic sequencing can provide clinically meaningful diagnoses in a substantial proportion of these patients. Prior work has demonstrated that WES yields a molecular diagnosis in approximately 25% of adults with unexplained liver disease.8,9 In 2019, a pilot cohort study demonstrated the identification of previously unrecognised monogenic disorders in adults with unexplained liver disease. These molecular diagnoses directly informed treatment and clinical management.8 More recently, follow-up studies with a larger number of patients with idiopathic liver disease further validated the clinical impact of genetic diagnoses in adult hepatology, including changes in surveillance strategies, therapeutic decision-making, and family counselling.9 Together, these findings underscore the growing role of genomic sequencing in the evaluation and management of adults with liver disease. WGS represents another approach to further increase diagnostic yield. By sequencing the entire genome, WGS enables detection of structural variants, copy number variants (CNVs), and pathogenic alterations in non-coding regulatory regions that may not be captured by exome sequencing. WGS also provides more uniform genome-wide coverage and improved detection of CNVs, as many CNV breakpoints occur outside exome-targeted regions.10 Comparative studies have shown that while most single-nucleotide variants and small insertions/deletions are detected by both WES and WGS, the latter can in some cases identify high-quality variants missed by WES due to improved coverage.10 Despite these potential advantages, the incremental diagnostic benefit of WGS over contemporary WES remains debated, especially in adult cohorts. Some studies demonstrate only modest improvements in diagnostic yield, whereas others report clinically meaningful additional diagnoses when WGS is used.11,12 Broader clinical adoption of WGS is limited by higher costs, increased data storage requirements, and challenges in interpreting non-coding variation, particularly for clinical decision making. To date, the application of WGS in adult liver disease remains elusive. This review synthesises the growing evidence supporting the use of genetic testing in the diagnosis and management of adults across a broad spectrum of liver diseases. Each section emphasises high-yield learning points and translates recent evidence into actionable clinical insights for real-world practice. Genetic testing for evaluation of cholestatic liver disease Cholestasis describes defective hepatic bile formation or impaired bile flow along the intra- and extrahepatic bile ducts into the small intestine. The aetiologies of cholestatic liver disease are heterogenous. Besides mechanical obstruction, autoimmune liver diseases, inflammation and infection, hormones, drugs or genetic variants can contribute to cholestasis development. Depending on the site of damage – hepatocyte vs. cholangiocyte – cholestasis can be divided into two major subtypes: primary cholestasis and cholangiopathies. In primary cholestasis, retention and accumulation of bile components, especially bile acids, results in hepatocyte injury, often reflected by elevated alanine aminotransferase, aspartate aminotransferase, serum bile acids, and/or bilirubin levels. In cholangiopathies, injury to the biliary epithelium is characterised by raised gamma-glutamyltransferase, alkaline phosphatase, and/or bilirubin values.13 Hereditary cholestasis and cholangiopathies may affect bile acid synthesis, nuclear signalling, vesicular intracellular trafficking, hepatocellular canalicular transport, maintenance of cell polarity of both hepatocytes and cholangiocytes, tight junction integrity, and ciliary structure and function on cholangiocytes.[13], [14], [15] While cholestasis- and cholangiopathy-associated genes were primarily identified in severe, early-onset forms of progressive familial intrahepatic cholestasis (PFIC),14,16 it has become apparent that late onset forms exist and that genetic variants in PFIC-associated genes may underlie idiopathic cholestasis in adults.8,9,13,[17], [18], [19] In the late 1990s, PFIC was linked to variants in genes encoding hepatobiliary transport proteins such as ATP8B1, encoding the aminophospholipid flippase familial intrahepatic cholestasis 1 (FIC1), ABCB11, encoding the hepatocyte-specific bile salt export pump (BSEP), and ABCB4, encoding the phospholipid floppase multidrug resistance protein (MDR3).[20], [21], [22] Disease-causing variants in ABCB4, ABCB11 and ATP8B1 are most frequently detected in adults with idiopathic cholestasis.17,18,23 In a recent analysis from the UK, variants in one of these genes were identified in almost 30% of adults with idiopathic cholestasis, which is in line with data from other cohorts.9,17,18,24 ABCB4 variants in adults tend to present with pregnancy-associated cholestasis, recurrent gallstone disease (low phospholipid-associated cholelithiasis syndrome) and/or chronic progressive liver disease, such as biliary fibrosis/cirrhosis or even cholangiocarcinoma.17,18,[25], [26], [27], [28], [29], [30], [31] For ABCB4 disease, bi-allelic rare loss-of-function variants tend to become apparent earlier in life.17,32 ABCB11 disease in adults may present as acute/episodic cholestasis, pregnancy-associated cholestasis, drug-induced cholestasis and in some cases even as late-onset PFIC.17,18,33,34 ATP8B1 disease in adults is less common than ABCB4 or ABCB11 disease and may become apparent as episodic/acute cholestasis, pregnancy-associated cholestasis or chronic liver disease.17,18,23,34 With increasing availability of NGS techniques, novel cholestasis- and cholangiopathy-associated genes have been identified. These include ZO-2 (TJP2), the nuclear receptor and transcription factor FXR (NR1H4), MYO5B, KIF12, USP53, ZFYVE19, SEMA7A, ABCC12, FGFR4, and LSR, among others.13,15,[35], [36], [37], [38], [39], [40], [41], [42], [43], [44], [45] Genetic variants detected in adults with idiopathic cholestasis tend to be monoallelic.17,18,34 In particular, in ABCB4 disease, cumulative bile duct damage appears to increase over time, such that individuals with heterozygous variants develop clinical symptoms later than those with biallelic variants, likely because they retain greater MDR3 function and consequently more residual protective biliary micelle formation.34 A ‘second trigger’, such as oestrogen-rich medications or pregnancy, may precipitate clinical manifestations. Moreover, monoallelic variants in more than one cholestasis-associated gene may predispose to overt cholestasis development.46 In such cases, hepatocyte-like cells generated from patient-derived induced pluripotent stem cells can be used to assess the pathogenicity of individual variants.46 Besides rare mono- and biallelic variants, more common variants in cholestasis-related genes may contribute to a clinically overt phenotype.47,48 In patients with primary biliary cholangitis (PBC), the presence of a common variant in ABCB4 (c.711A>T, rs2109505) increased the risk of cirrhosis development 1.8-fold.49 PBC and primary sclerosing cholangitis (PSC) are complex traits, where the clinical phenotype is controlled by an intricate interaction between genetic variants and different environmental factors.50,51 Genome-wide association studies (GWAS) have identified multiple HLA and non-HLA susceptibility loci in PBC.50 The latter seem to predominately modulate immune functions (e.g. IL12A, STAT4, CCL20, IL12RB2, CD80) and hitherto no genetic variants affecting cholangiocyte biology have been detected.50,51 Genetic testing is not part of the diagnostic algorithm for PBC, but may be warranted in individuals with atypical presentation (seronegative PBC). Similarly, GWAS in PSC identified multiple risk loci within HLA and non-HLA regions.[52], [53], [54] In contrast to PBC, loci affecting cholangiocyte biology (e.g. GPC6, TGR5/GPBAR1) were described.52 ABCB4 disease can mimic the clinical and histopathological features of PSC.55 Genetic cholangiopathies, such as ABCB4 disease, should be considered in the differential diagnosis of PSC, particularly in patients with small-duct PSC, no inflammatory bowel disease, or other atypical features. Learning point: Genetic testing allows for a definitive diagnosis in at least 20-30% of individuals with idiopathic cholestasis.17,24 Actionable clinical insight: Genetic testing (cholestasis gene panel, WES and/or WGS) is recommended for suspected hereditary cholestasis and for idiopathic cholangiopathies after exclusion of more common aetiologies (Graphical abstract, Table 1).56,57Table 1Summary of genetic testing learning points and their translation to clinical practice.Table 1Clinical presentationLearning pointActionable clinical insightCholestasis•Genetic testing enables a definitive diagnosis in at least 20-30% of individuals with idiopathic cholestasis and/or cholangiopathy.•Genetic testing (cholestasis gene panel, WES and/or WGS) is recommended for suspected hereditary cholestasis and for idiopathic cholangiopathies after exclusion of more common aetiologies.Hepatic steatosis•Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have unrecognised monogenic diseases.•Genetic testing (WES) is recommended for evaluation of lean adults with unexplained hepatic steatosis and no visceral adiposity.Cryptogenic cirrhosis•Multiple rare monogenic diseases have been described in adults with cryptogenic cirrhosis.•Genetic testing (WES) is recommended for evaluation of adults with cryptogenic cirrhosis and previously unrevealing comprehensive work-up.Portal hypertension•A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or PSVD.•Genetic testing (WES) is recommended for evaluation of adults with non-cirrhotic portal hypertension or PSVD of unclear aetiology.Acute liver failure (ALF)•Rapid WGS is now an integral part of the evaluation of ALF in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult ALF of unclear aetiology remains undefined.•If faced with a case of ALF of unknown aetiology despite a comprehensive work-up, WES or WGS should be considered to assess for an atypical presentation of a known monogenic disease.Hepatology Genome Rounds•Like Liver Tumour Boards, Hepatology Genome Rounds represent multidisciplinary forum that would be progressively integrated in centres with expertise in Hepatology.•Interdisciplinary Case Discussion, e.g. within the ERN RARE Liver•Patients with atypical liver disease presentation of suspected genetic disorders should be reviewed and discussed in multidisciplinary Hepatology Genome Rounds or referred to a centre with genomic hepatology expertise.WES, whole-exome sequencing; WGS, whole-genome sequencing; ERN, European Reference Network; PSVD, porto-sinusoidal vascular disease; ALF, acute liver failure. Table 1Summary of genetic testing learning points and their translation to clinical practice.Table 1Clinical presentationLearning pointActionable clinical insightCholestasis•Genetic testing enables a definitive diagnosis in at least 20-30% of individuals with idiopathic cholestasis and/or cholangiopathy.•Genetic testing (cholestasis gene panel, WES and/or WGS) is recommended for suspected hereditary cholestasis and for idiopathic cholangiopathies after exclusion of more common aetiologies.Hepatic steatosis•Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have unrecognised monogenic diseases.•Genetic testing (WES) is recommended for evaluation of lean adults with unexplained hepatic steatosis and no visceral adiposity.Cryptogenic cirrhosis•Multiple rare monogenic diseases have been described in adults with cryptogenic cirrhosis.•Genetic testing (WES) is recommended for evaluation of adults with cryptogenic cirrhosis and previously unrevealing comprehensive work-up.Portal hypertension•A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or PSVD.•Genetic testing (WES) is recommended for evaluation of adults with non-cirrhotic portal hypertension or PSVD of unclear aetiology.Acute liver failure (ALF)•Rapid WGS is now an integral part of the evaluation of ALF in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult ALF of unclear aetiology remains undefined.•If faced with a case of ALF of unknown aetiology despite a comprehensive work-up, WES or WGS should be considered to assess for an atypical presentation of a known monogenic disease.Hepatology Genome Rounds•Like Liver Tumour Boards, Hepatology Genome Rounds represent multidisciplinary forum that would be progressively integrated in centres with expertise in Hepatology.•Interdisciplinary Case Discussion, e.g. within the ERN RARE Liver•Patients with atypical liver disease presentation of suspected genetic disorders should be reviewed and discussed in multidisciplinary Hepatology Genome Rounds or referred to a centre with genomic hepatology expertise.WES, whole-exome sequencing; WGS, whole-genome sequencing; ERN, European Reference Network; PSVD, porto-sinusoidal vascular disease; ALF, acute liver failure. Summary of genetic testing learning points and their translation to clinical practice. •Genetic testing enables a definitive diagnosis in at least 20-30% of individuals with idiopathic cholestasis and/or cholangiopathy. Genetic testing enables a definitive diagnosis in at least 20-30% of individuals with idiopathic cholestasis and/or cholangiopathy. •Genetic testing (cholestasis gene panel, WES and/or WGS) is recommended for suspected hereditary cholestasis and for idiopathic cholangiopathies after exclusion of more common aetiologies. Genetic testing (cholestasis gene panel, WES and/or WGS) is recommended for suspected hereditary cholestasis and for idiopathic cholangiopathies after exclusion of more common aetiologies. •Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have unrecognised monogenic diseases. Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have unrecognised monogenic diseases. •Genetic testing (WES) is recommended for evaluation of lean adults with unexplained hepatic steatosis and no visceral adiposity. Genetic testing (WES) is recommended for evaluation of lean adults with unexplained hepatic steatosis and no visceral adiposity. •Multiple rare monogenic diseases have been described in adults with cryptogenic cirrhosis. Multiple rare monogenic diseases have been described in adults with cryptogenic cirrhosis. •Genetic testing (WES) is recommended for evaluation of adults with cryptogenic cirrhosis and previously unrevealing comprehensive work-up. Genetic testing (WES) is recommended for evaluation of adults with cryptogenic cirrhosis and previously unrevealing comprehensive work-up. •A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or PSVD. A rising number of rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or PSVD. •Genetic testing (WES) is recommended for evaluation of adults with non-cirrhotic portal hypertension or PSVD of unclear aetiology. Genetic testing (WES) is recommended for evaluation of adults with non-cirrhotic portal hypertension or PSVD of unclear aetiology. •Rapid WGS is now an integral part of the evaluation of ALF in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult ALF of unclear aetiology remains undefined. Rapid WGS is now an integral part of the evaluation of ALF in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult ALF of unclear aetiology remains undefined. •If faced with a case of ALF of unknown aetiology despite a comprehensive work-up, WES or WGS should be considered to assess for an atypical presentation of a known monogenic disease. If faced with a case of ALF of unknown aetiology despite a comprehensive work-up, WES or WGS should be considered to assess for an atypical presentation of a known monogenic disease. •Like Liver Tumour Boards, Hepatology Genome Rounds represent multidisciplinary forum that would be progressively integrated in centres with expertise in Hepatology. Like Liver Tumour Boards, Hepatology Genome Rounds represent multidisciplinary forum that would be progressively integrated in centres with expertise in Hepatology. •Interdisciplinary Case Discussion, e.g. within the ERN RARE Liver Interdisciplinary Case Discussion, e.g. within the ERN RARE Liver •Patients with atypical liver disease presentation of suspected genetic disorders should be reviewed and discussed in multidisciplinary Hepatology Genome Rounds or referred to a centre with genomic hepatology expertise. Patients with atypical liver disease presentation of suspected genetic disorders should be reviewed and discussed in multidisciplinary Hepatology Genome Rounds or referred to a centre with genomic hepatology expertise. WES, whole-exome sequencing; WGS, whole-genome sequencing; ERN, European Reference Network; PSVD, porto-sinusoidal vascular disease; ALF, acute liver failure. Genetic testing for evaluation of unexplained hepatic steatosis Hepatic steatosis has traditionally been defined as the accumulation of triglycerides in the cytoplasm of more than 5% of hepatocytes. Interestingly, a recent study found that the 95th percentile of hepatic triglyceride content in lean non-Asian Indian individuals was significantly lower at 1.85%, and concentrations above this threshold were associated with insulin resistance and cardiovascular risk factors.58 Hepatic steatosis represents a broad phenotypic spectrum arising from diverse aetiologies. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease worldwide.59 Genetic variation plays a significant role in MASLD susceptibility and progression, largely through a combination of risk and protective alleles (complex polygenic disorder).60 On the other hand, approximately 10–20% of cases of hepatic steatosis occur in lean individuals (BMI <25 kg/m2),59 often in the absence of metabolic risk factors. In this latter subgroup, rare variants in a single gene are identified as the cause of disease in some cases.61 Among lean patients with otherwise unexplained steatotic liver disease, WES has identified several rare monogenic causes explaining the abnormal triglyceride accumulation in hepatocytes. These include disorders of lipid metabolism, lipodystrophy syndromes, and mitochondrial diseases, among other rare diseases. For instance, a familial form of steatotic liver disease has been associated with a monoallelic mutation in ABHD5.62 Furthermore, WES performed in a cohort of six lean individuals without visceral adiposity and biopsy-proven steatotic liver disease found that 33% of them had an underlying monogenic disorder. Diagnoses included hereditary fructose intolerance due to a homozygous ALDOLB mutation and heterozygous familial hypobetalipoproteinemia due to an APOB variant, supported by both functional and population-level data.63 Accurate identification of monogenic disease can have direct therapeutic implications. In a cohort study, a lean patient with severe hepatic steatosis of unclear aetiology was found to harbour a rare mutation in PPARG, which encodes the peroxisome proliferator-activated receptor gamma protein, establishing the diagnosis of familial partial lipodystrophy type 3. Since PPARG is a transcription factor critical for adipocyte differentiation, this patient presented with reduced adipose tissue throughout the body (with preserved subcutaneous adipose tissue in the face and neck), explaining the triglyceride accumulation in the circulation and in the liver. This diagnosis enabled initiation of leptin replacement therapy, resulting in substantial improvement in dyslipidaemia and a 50% reduction in insulin requirements.8 This example highlights the clinical utility of genetic diagnosis in guiding targeted treatment. While monogenic disorders account for a subset of cases of unexplained hepatic steatosis, the genetic architecture of MASLD is primarily polygenic. GWAS have identified multiple common genetic variants that increase susceptibility but are not independently sufficient to cause disease. Commonly implicated variants include PNPLA3, TM6SF2, MBOAT7, GCKR, and HSD17B13, which are associated with differences in steatosis severity, inflammation, fibrosis progression, cirrhosis risk, hepatocellular carcinoma, and mortality.64 These variants also influence specific metabolic pathways. For example, GCKR and TM6SF2 variants are associated with increased de novo lipogenesis, suggesting that carriers may preferentially benefit from therapies targeting this pathway.65 The PNPLA3 I148M variant, one of the strongest genetic risk factors for MASLD, is associated with increased risk of steatohepatitis, fibrosis progression, and hepatocellular carcinoma.66 In addition to variants that increase risk, some germline and somatic mutations have been shown to be protective against MASLD.[67], [68], [69] For example, rare germline mutations in CIDEB, which encodes a structural protein in hepatic lipid droplets, are associated with 33% lower odds of liver disease from any cause.70 Similarly, loss of function mutations in HSD17B13, another lipid droplet-associated protein, are linked to slower histologic progression of MASLD.71 There is also evidence that certain somatic variants, including those in PKD1 and ARID1A, can have hepatoprotective effects.72 Learning point: Up to 30% of lean adults with hepatic steatosis and no visceral adiposity have unappreciated monogenic diseases.8,9,61,63 Actionable clinical insight: Genetic testing (WES) is recommended for evaluation of lean adults with unexplained hepatic steatosis and no visceral adiposity (Graphical abstract, Table 1).61 Genetic testing for evaluation of cryptogenic cirrhosis In about 5-30% of individuals with cirrhosis, the aetiology remains elusive despite extensive workup including liver biopsy.73,74 Historically, MASLD has been suspected to account for the majority of these cases as macro-steatosis may paradoxically diminish as cirrhosis progresses.73 A recent study from India reports that liver biopsy allowed a definitive diagnosis in 10% of individuals with suspected cryptogenic cirrhosis after comprehensive clinical and laboratory testing.75 MASLD and autoimmune hepatitis (AIH) accounted for 33% and 43% of cases, respectively, while features of both MASLD and AIH were found in 17% of cases. Wilson’s disease was histologically diagnosed in two cases.75 Using serological antibody testing and upper endoscopy with duodenal biopsy sampling, coeliac disease was identified as the underlying aetiology in 5% of cases with suspected cryptogenic cirrhosis.73,75 An analysis of individuals listed for liver transplantation in the UNOS (United Network for Organ Sharing) database found that those with cryptogenic cirrhosis were distinct from those with cirrhosis related to metabolic dysfunction-associated steatohepatitis, AIH, or alcohol-related liver disease, supporting the hypothesis that a detailed diagnostic workup of cryptogenic cirrhosis may reveal less common or previously unrecognised causes of chronic liver disease.76 Genetic analysis is currently underused in individuals with cryptogenic cirrhosis. An analysis across UK transplant centres revealed that only 24% of persons listed for liver transplantation for cryptogenic cirrhosis (n = 165) between 2015-2020 received some form of genetic testing.77 WES was used in only one person (less than 1% of cases), multi-gene panels were applied in 8%, while single gene analysis for HFE (hereditary haemochromatosis) or ATP7B (Wilson’s disease) gene variants was applied most frequently.77 This is somewhat surprising as different cohorts demonstrated a diagnostic yield for WES of about 12-30% for the detection of monogenic causes in adults with idiopathic liver disease as well as cryptogenic cirrhosis.8,9,78,79 The number of genes associated with monogenic chronic liver disease and cirrhosis is still increasing.19,80 Genes associated with common hereditary liver diseases include HFE, HJV, HAMP, TFR2, and SLC40A1 (hereditary haemochromatosis), SERPINA1 (alpha-1 antitrypsin deficiency), and CFTR (cystic fibrosis), which together represent some of the most frequent inherited liver diseases in populations of European ancestry.[81], [82], [83] Additionally, pathogenic variants in ATP7B, ABCB4, TULP3, FOCAD and in genes affecting telomere maintenance have been identified in adults with cryptogenic cirrhosis.8,9,27,84,85 ABCB4 disease can present as biliary fibrosis without overt cholestasis and thus be misclassified as cryptogenic cirrhosis.8 TULP3 variants were initially identified in two adults presenting with fibrocystic kidney disease, hypertrophic non-obstructive cardiomyopathy and slowly progressive liver disease resulting in cirrhosis.84 FOCAD variants were first described in children with cryptogenic cirrhosis.85 Loss of function of FOCAD was associated with altered cytoplasmic mRNA degradation via the super killer mRNA surveillance complex and increased chemokine expression in hepatocytes.85 Recently, a FOCAD variant was described in an adult with cryptogenic cirrhosis, indicating that FOCAD disease may also present later in life.78 Liver disease is found in about 40% of individuals with telomere biology disorders (TBD), which are characterised by shortened telomere length. Variants in a number of genes have been associated with TBD, including TERT, TERC, TINF2, DKC1, PARN, and RTEL1.86,87 In individuals with suspected TBD, telomere length can be measured in peripheral blood leukocytes.88 Diagnosis is confirmed by genetic testing, which yielded a diagnosis in over 80% of cases with TBD-associated liver disease.86 In patients with TBD-associated advanced liver disease requiring liver transplantation, genetic analysis remained inconclusive in 25% of cases.86 Inherited metabolic disorders, such as glycogen storage disorders, lysosomal storage disorders, lysosomal acid lipase deficiency, organic acidaemias, urea cycle disorders, tyrosinemia type I and mitochondrial diseases lead to a broad spectrum of liver involvement, including cirrhosis development, and should be considered in individuals with cryptogenic chronic liver disease.89 Genetic analysis in cryptogenic cirrhosis may not only reveal potential monogenic variants explaining the clinical presentation but may identify variants that predispose to liver disease development and/or disease progression.70,90,91 Carrier status for the pathogenic Z-allele (Pi∗MZ) of SERPINA1 has been shown to influence liver disease progression independently of underlying aetiology.[92], [93], [94] Learning point: Multiple rare monogenic diseases have been described in adults with cryptogenic cirrhosis. Actionable clinical insight: Genetic testing (WES) is recommended for evaluation of adults with cryptogenic cirrhosis despite a comprehensive work-up (Graphical abstract, Table 1).95,96 Genetic testing for unexplained portal hypertension Portal hypertension may result from prehepatic causes (e.g. portal or splenic vein thrombosis), intrahepatic causes (most commonly cirrhosis), or posthepatic causes (e.g. Budd-Chiari syndrome). The majority of cases are intrahepatic with cirrhosis being the primary driver.97 The genetic contribution to portal hypertension has not been well established and has largely been considered indirect, often reflecting genetic susceptibility to underlying liver diseases that progress to cirrhosis and portal hypertension.97 Additionally, the complex interplay of parenchymal injury and vascular remodelling in cirrhosis has made it challenging to isolate specific genetic determinants. In rare cases, it is important to recognise that portal hypertension may occur in the absence of cirrhosis, a condition known as non-cirrhotic portal hypertension or portal sinusoidal vascular disease (PSVD). Although the precise pathophysiology remains unclear, PSVD has been associated with haematologic disorders, infections, medication exposures, and inherited conditions.98 To date, 35 genes and one chromosomal abnormality have been associated with PSVD.99 These cases can be broadly categorised into a primary PSVD phenotype or multisystemic disorders with extrahepatic manifestations. The latter encompasses Adams–Oliver syndrome, TBD, cystic fibrosis, and primary immunodeficiencies. Recent WES studies have further supported a genetic basis for PSVD, with identification of disease-causing variants in multiple genes, including KCNN3, DGUOK, FOPV, GIMAP5, FCHSD1, TRMT5, and HRG.96 Three affected individuals with the same father but different mothers presented with non-cirrhotic portal hypertension and were found to carry a rare KCNN3 mutation, which encodes a small-conductance calcium-activated potassium channel.100 GIMAP5 variants were identified through WES in four unrelated families with unexplained portal hypertension.101 Interestingly, in the liver, GIMAP5 is selectively expressed in endothelial cells.101,102 Discovery of monogenic deficiencies that result in PSVD is largely based on small cohorts, involving one to four affected families. The age of presentation of genetic PSVD varies. For example, GIMAP5 deficiency can present clinically both in childhood and adulthood.101,103,104 Given the limited understanding of PSVD biology, monogenic forms of the disease provide a valuable framework for elucidating its underlying cellular and molecular mechanisms. Learning point: Several rare monogenic diseases have been described in adults with non-cirrhotic portal hypertension or PSVD. Actionable clinical insight: Genetic testing (WES) is recommended for evaluation of adults with non-cirrhotic portal hypertension or PSVD of unclear aetiology (Graphical abstract, Table 1).95,105 Genetic testing for acute liver failure In neonatal and paediatric patients, acute liver failure (ALF) is frequently a severe clinical presentation of a diverse group of inherited metabolic disorders and other monogenic liver diseases, supporting the use of rapid WGS in the diagnostic work-up.106,107 In contrast, the contribution of monogenic disorders to ALF in adults remains poorly defined, highlighting the need for studies evaluating genomic analysis in adults with ALF of unclear aetiology. Learning point: Rapid WGS is now an integral part of the evaluation of ALF in newborns and children due to a high prevalence of monogenic causes, whereas its role in adult ALF of unclear aetiology remains undefined. Actionable clinical insight: If faced with a case of ALF of unknown aetiology despite a comprehensive work-up, WES or WGS should be considered to assess for an atypical presentation of a known monogenic disease (Graphical abstract, Table 1). Multidisciplinary Hepatology Genome Rounds Genetic causes account for a substantial proportion of cases across the spectrum of liver diseases. Despite these contributions, genetic testing remains underutilised in hepatology.8,80 Barriers to the integration of genomic medicine include a limited genetics workforce, insufficient clinician knowledge regarding test selection and result interpretation, inadequate financial coverage, and a degree of scepticism regarding clinical utility.105,108 To address some of these gaps, our group launched Hepatology Genome Rounds in 2021. This multidisciplinary forum brings together hepatologists, pathologists, geneticists, fellows, and medical students with the dual goals of improving patient care, educating clinicians, and expanding genotype–phenotype correlations across the broader patient population (Graphical abstract, Fig. 1).Fig. 1Projected integration of genomic medicine into routine clinical practice in adult hepatology clinics. Projected integration of genomic medicine into routine clinical practice in adult hepatology clinics. Hepatology Genome Rounds foster cross-specialty collaboration in the diagnosis and management of atypical cases and poorly understood clinical presentations of liver disease. The value of interdisciplinary discussion is well established within the liver community through multidisciplinary liver tumour boards. These forums have been shown to reduce the time from diagnosis to treatment and to positively impact survival outcomes.[109], [110], [111] We predict that Hepatology Genome Rounds will be increasingly adopted by many liver centres across the globe to strengthen the integration of genomic medicine into clinical practice. For patients with unclear diagnoses, discussion at Genome Rounds can directly inform management decisions. In some cases, WES yields a clear molecular diagnosis; in others, it identifies rare variants classified as variants of uncertain significance (VUS), which lack sufficient evidence to be categorised as either benign or pathogenic. WES may identify a VUS in a gene associated with a known syndrome that is not fully consistent with the patient’s phenotype. For example, a patient with features suggestive of a genetic disorder – early onset (<40 years), atypical presentation, syndromic features, and a positive family history of liver disease – may have only a VUS in a gene not previously associated with liver disease. Following multidisciplinary discussion at Hepatology Genome Rounds, the team determined that this variant was likely not the cause of the patient’s condition, and additional testing was warranted given the high clinical suspicion of a genetic aetiology. This included recommending WGS to identify possible disease-causing genetic alterations not captured by WES. This case illustrates how Genome Rounds can prompt additional diagnostic evaluation. Similar discussions have led to reassessment of diagnoses and recommendations for further testing in multiple patients.105 Hepatology Genome Rounds have also helped drive the development of best practices for integrating genomic medicine into liver disease care. The forum serves as an important educational venue for both providers and trainees, helping participants stay up to date with genomic principles in hepatology, address knowledge and skill gaps, and deepen understanding of the clinical role of genetic testing. At our centre, this approach has, over time, led to greater adoption of genetic testing among clinical hepatologists in real world practice. Although Hepatology Genome Rounds continue to evolve, they have already demonstrated meaningful benefits for clinicians, trainees, and patients over the past five years.105 The model has begun to expand to other centres, with the long-term goal of establishing a multi-institutional hybrid forum that can further advance these clinical and educational objectives. Learning point: Like Liver Tumour and Molecular Tumour Boards, Hepatology Genome Rounds represent a multidisciplinary forum that should be progressively integrated into centres with expertise in hepatology. Actionable clinical insight: Patients with atypical liver disease presentation of suspected genetic disorders should be reviewed and discussed in multidisciplinary Hepatology Genome Rounds or referred to a centre with genomic hepatology expertise (Graphical abstract, Table 1).105 Genetic testing in the liver clinic: The present and the future In adults with suspected acute or chronic liver disease, the current approach to diagnosis differs depending on suspected aetiology but is typically a stepwise approach. In most cases, the diagnostic workup comprises a comprehensive history including family history, physical examination, abdominal ultrasound and liver stiffness measurements. MRI, including MR-proton density fat fraction, MR-elastography and MR cholangiopancreatography may help to establish a diagnosis. If still uncertain, liver biopsy is usually the next step in those with chronic liver disease. Genetic testing is underused even in patients listed for liver transplantation due to cryptogenic cirrhosis.77 However, guidelines for cholestatic liver diseases such as PSC and for individuals with suspected hereditary cholestasis recommend genetic testing as part of their diagnostic algorithms.56,57 The use of gene panels or WES in cholestasis of unknown aetiology has been integrated into the diagnostic workup of many centres.13 For MASLD, current guidelines recommend targeted genetic testing for secondary/alternate causes of liver steatosis, such as lysosomal acid lipase deficiency and WD, as well as the use of WES to diagnose potential inherited metabolic diseases.112,113 When considering genetic testing, gene panels may enable cost-effective and rapid analysis; however, they have the disadvantage that newly discovered liver disease-associated genes are generally not included. WES and WGS approaches overcome this problem and enable the use of “virtual gene panels” during analysis. If this first round of analysis does not yield a potential candidate variant or variants, a more comprehensive analysis can be conducted.9,13,105 Moreover, re-analysis can be performed and repeated at later time points if novel patient-related information or novel liver disease-associated genes become known (Fig. 1). Another advantage of WES and WGS is the detection of newly described disease-modifier variants, which may provide prognostic insight. While the clinical value of genetic testing is well-established and costs are expected to continue decreasing, which will make WES and WGS available to many physicians and healthcare professionals, several challenges remain in implementing WES and WGS into the routine diagnostic workup. In addition to conducting genetic testing, a comprehensive infrastructure is required to support effective clinical implementation (Fig. 1).77 This includes access to genetic counselling, testing of family members, and referral pathways for further care, especially if the detected variants affect other organ systems. Another challenge lies in the vast number of VUS and their interpretation and further evaluation. Multidisciplinary genetic/genome rounds can address this challenge and have been implemented in a small number of tertiary care centres (Fig. 1).105 Another approach is through multidisciplinary case discussions such as those held within the European Reference Network for Rare Liver Diseases (ERN-RARE Liver).114 While the measures described are already available, it is envisioned that in the future the question of who, when (in the diagnostic workflow) and how (targeted gene panels, WES, WGS) to test will be replaced by broad genetic testing. Furthermore, as many patients will have undergone liver biopsy, results from germline genetic analysis can be combined with transcriptomic analysis, thereby reclassifying some of the detected VUS. For example, in a patient with severe progressive cholestasis requiring liver transplantation, identification of a missense variant in the nuclear bile acid receptor FXR was supported by markedly reduced or absent expression of FXR target genes in liver biopsy material, consistent with the suspected FXR variant’s pathogenicity.115 In a recent study, the addition of RNA-seq helped to establish a diagnosis in nearly 19% of patients previously undiagnosed after genetic analysis. RNA-seq helped identify and confirm potential splice variants and allele-specific expression.116 Artificial intelligence-driven integration of proteomic and metabolomic biomarkers may further enhance the diagnostic yield but raises complex methodological, ethical, and regulatory challenges.117 WES and WGS will become an integral part of the hepatologist’s diagnostic armamentarium. Knowledge of both rare disease-associated variants and more frequent liver disease-modifying variants offers opportunities for risk stratification and novel therapeutic approaches. However, these diagnostic advances need to be embedded into an infrastructure that includes genetic counselling, multidisciplinary discussion of genetic findings, and referral networks to support long-term specialist care for all affected organ systems. Use of artificial intelligence-based methods promises more rapid and precise interpretation of genetic variants through complex integration of available deep phenotyping, biomarkers and transcriptome data (Fig. 1). Abbreviations AIH, autoimmune hepatitis; ALF, acute liver failure; CNV, copy number variant; ERN-RARE Liver, European Reference Network for Rare Liver Diseases; GWAS, genome-wide association study; HCC, hepatocellular carcinoma; MASLD, metabolic dysfunction-associated steatotic liver disease; NGS, next-generation sequencing; PBC, primary biliary cholangitis; PFIC, progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis; PSVD, portal sinusoidal vascular disease; RNA-seq, RNA sequencing; VUS, variant of uncertain significance; WES, whole-exome sequencing; WGS, whole-genome sequencing. Authors’ contributions SV designed the manuscript and AM and SV created the graphical abstract/figure/table. VK, AM, CD and SV wrote the manuscript, and all approved the final version. Financial support SV is supported by 10.13039/100000002NIH-10.13039/100000062NIDDK, R01 DK131033. AM is supported by 10.13039/100000002NIH/10.13039/100000062NIDDK, 5T35DK104689. VK and CD are supported by BMFTR (Federal Ministry of Research, Technology and Space, Germany) through HiChol (01GM1904A and 01GM2204A). Conflicts of interest No author received funding for this publication. VK received honoraria for speaker’s corner from Falk, Mirum, Ipsen, GSK, Gilead, MSD and participated in advisory boards by Mirum, Ipsen, Falk, GSK and AstraZeneca. CD received speaker’s honoraria and travel reimbursements from Falk and Mirum, payment for manuscript writing from Falk, and participated in advisory board by Mirum. SV served as consultant for Mirum and Ipsen and received research grant support from Moderna Therapeutics and Mirum. Please refer to the accompanying ICMJE disclosure forms for further details.